Key Takeaways
- Profit surged, driven by exports: PAT grew ~3.5x YoY, with full-year guidance raised past ₹1,200 crores; a significant portion of the quarter's profit came from non-Revlimid products and a one-time tender order.
- Revlimid tail continues, with a March reload: Contribution dipped QoQ in Q3, but a new quota allocation begins in March, and management expects things to improve from that point.
- The pipeline is the thesis, not the quarter: Management pointed to 2-3 near-term U.S. launches, a target to double smart FTFs to 6-7 in two years, and a 5-8 year bet on complex generics and oligopeptides as the real drivers of the next cycle.
- Cash is building, and patience is the M&A strategy: With the large capex cycle over, cash is accumulating; management is scouting for a large acquisition in Emerging Markets but has a high hurdle rate (higher teens to 20% return) and has found domestic targets too expensive.
- What to watch next quarter: The size and sustainability of the March Revlimid reload, any FDA classification on the Kothur facility, and whether FY25 guidance reveals a post-Revlimid growth path.
The Revlimid Trajectory
- Q3 dip, Q4 reload: Revlimid contribution was lower in Q3 than in Q2, but a new quota allocation begins in March, and management expects to do well in the March quarter.
- Third-year dynamics: The period from March 2024 to February 2025 marks the third year for Revlimid; management says it is too early to comment on EBITDA margins or contribution levels for that period.
- Competitive erosion is real but managed: Significant erosion has occurred in the market, but Natco is happy with its position; Teva sells Natco's product, and more clarity on the trajectory will come in May when March numbers are available.
- Geographic expansion continues: The product is doing well in Canada, has launched in Australia, and the company is looking at 1 or 2 other Rest of World markets.
Rajeev Nannapaneni: "Every company goes through a cycle where you make money on one product, and it falls away. And I think the way you need to judge a company is what pipeline do you have and what's going to be the next big product."
Pipeline: The Next Big Products
- Near-term U.S. launches: Management committed to delivering at least 2 or 3 products as interesting as semaglutide and Olaparib in the next 12 months, with a hope to announce a filing achievement.
- First-to-file target doubled: The company wants to grow from 3-4 smart FTFs to 6-7 in the next 2 years, aiming for more consistency in the launch cadence.
- Para IV assets in play: Key disclosed opportunities include sole FTFs on Bosentan 32mg and Carfilzomib 10mg, plus Olaparib, Semaglutide, trabectedin, and pomalidomide.
- Complex generics as the long game: 3 or 4 complex generics are in development; succeeding at even 1 or 2 would add a disruptive launch, with the target of 6-7 for more consistent output over a 5-6 year horizon.
- Oligopeptide filing: The company hopes to get a filing through in the next 12 months, with a payoff that may be 5 to 8 years away.
- Semaglutide is partnered and distant: The product is partnered with Mylan, so Natco does not retain 100% of the economics; the compound patent runs past 2030, litigation is ongoing, and management cannot provide timelines on development, filing, or launch.
- Imbruvica setback: The company lost its appeal and is evaluating how to deal with the legal situation, with no specifics offered.
- Pomalidomide launch underway: Launched as the first generic in India, and in Canada and Australia; the U.S. has a launch date but it is a shared FTF with what management believes are 4 or 5 players.
Non-Pharma Bets: Crop Health & Agrochem
- Crop Health Sciences slowed by weather: December is a seasonally slower quarter, and the sector faced headwinds from weather patterns and the El Niño effect disrupting key crops; year-to-date revenue is roughly ₹110 crores.
- Full-year guidance trimmed to lower end: The guidance range is ₹150-200 crores, but management expects to land on the lower side due to lower offtake.
- Agrochem building a branded base: The business may end the year around ₹150-160 crores, a little lower than expected but still good for a completely new entrant; it is not making much money yet, with the first phase of market formation being the key milestone.
- First-time generic launches ahead: Very exciting launches, including a lot of first-time generics, are lined up in the next 12 months, subject to litigation outcomes.
- Exports are a 2-3 year story: International registrations have started in the U.S., Australia, and the Middle East, but exports will not kick in meaningfully for 2-3 years; the core strategy remains driven by the India branded business.
- Revenue potential: The agrochem business has the potential to reach ₹300-400 crores.
Capital Allocation: Cash, M&A, and Returns
- Capex cycle is over: The large capex phase that built the Vizag facility, the agrochemical facility, and expanded existing sites is complete; current spend is maintenance capex only, and cash is increasing because the company is not spending much on capex.
- M&A ambition is large and patient: Management is scouting for a big, large acquisition in Emerging Markets rather than smaller deals; no deal is on hand, but the search is active.
- Hurdle rate is deliberately high: The company looks for higher teens or 20% return on capital; management has passed on domestic formulation deals because expected returns were only slightly better than bank lending rates.
- All cash deployment options open: The company is preserving money for an acquisition but has done buybacks in the past and pays a reasonable dividend; all options remain on the table.
- Strategic investment in Singapore entity: A small original investment (2-3%) with an antidilution clause has grown to a 7% stake because of dilution protection.
- Cellogen Therapeutics: A $2 million commitment in a CAR T-cell therapy startup with a promising molecule; the investment may be increased if things go well.
Rajeev Nannapaneni: "I have very high expectations. I think we usually look for higher teens or 20% is my expectation. I don't like doing 10%, 12% transactions. I'm not a big fan of those because my hurdle has been so high, it's been difficult to do transactions. But I think we are sharp and we're patient."
Base Business & Operational Updates
- U.S. base business is stable: Copaxone remains the biggest product and the #1 generic with very good market share; Everolimus, Lanthanum, and Lapatinib are doing well; all key products are supplied from both Vizag and Hyderabad sites, with stable revenue and stable pricing.
- Domestic formulation is flat: The quarterly run rate is flattish around ₹100 crores; oncology volume is growing, but launches of interesting pipeline products are not in the near term, and acquiring a portfolio for the large GP segment has been blocked by high valuations.
- Subsidiaries contributed ₹163 crores: Driven primarily by Canada and Brazil; a one-time tender order in one market boosted emerging market profits this quarter.
- New subsidiaries in Colombia and Indonesia: The company is starting new subsidiaries in both countries, extending its RoW footprint.
- Kothur facility awaiting FDA classification: The company has replied to the FDA about corrective actions post-inspection and completed all remedial measures, but no classification has been received yet.
- Red Sea disruption is manageable: Freight rates are up 50-60% and air freight is also up dramatically, but Natco's portfolio is relatively less affected because it is high-value, small-volume product often sent by air.
- China raw material pricing is stable: Raw material pricing from China is fairly stable as of now.
- R&D spend target: The company strives to spend a minimum of 6-8% of revenue on R&D, sometimes 8-10% depending on the year.
Rajeev Nannapaneni: "The only thing going to make money in this business, one, you have complex generics, difficult-to-do products. Two, we have global reach. And you have a steady, branded generic business. I think these are the 3 ways you can make money. And I think out of these 3, you need to get at least 1 -- at least 2 things right and I think that's what will get you home."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 PAT | Expect to go past ₹1,200 crores (higher end of earlier ₹1,000-1,200 crores guidance) | FY24 full year |
| FY24 Sales | Expecting a little less than ₹4,000 crores | FY24 full year |
| Tax rate | Expectation of around 16-17% continuing | Going forward |
| Crop Health revenue | Guidance range ₹150-200 crores, likely on the lower side | FY24 |
| U.S. pipeline delivery | At least 2 or 3 products as interesting as semaglutide and Olaparib | Next 12 months |
| FTF target | Grow from 3-4 to 6-7 smart FTFs | Next 2 years |
| Oligopeptide filing | Hoping to get a filing through | Next 12 months |
| Agrochem exports | Exports won't kick in; some markets opening, major markets in 2-3 years | 2-3 years |
| FY25 guidance | Will guide for March 2024; may have more clarity | Next call |
| Revlimid quota clarity | Will give more color when March numbers are available | May |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated total revenue | ₹795.6 cr, +55% YoY |
| Net profit (consolidated) | ₹212.7 cr, ~3.5x vs ₹62.3 cr in Q3 FY23 |
| Formulation exports revenue | ₹605.6 cr |
| Formulation domestic revenue | ₹99.4 cr |
| API revenue | ₹46.3 cr |
| Crop health revenue | ₹14.1 cr |
| Revenue from all subsidiaries | ₹163 cr, primarily driven by Canada and Brazil |
| EBITDA (9 months YTD) | ₹1,340 cr |
| PAT (9 months YTD) | ₹1,000 cr |
| Capex (9 months YTD) | ₹282 cr |
| Tax rate expectation | 16% to 17%, expected to continue going forward |
| FY24 PAT expectation | Hoping to go past ₹1,200 cr |
| FY24 sales expectation | A little less than ₹4,000 cr |
| Crop health revenue (9 months YTD) | ~₹110 cr |
| Crop health FY24 expected revenue | ₹150 cr to ₹160 cr, lower end of ₹150 cr to ₹200 cr guidance |
| Domestic formulation oncology share | 60% to 65% of domestic portfolio |
| Freight rates increase | 50% to 60% increase due to Red Sea disruption |
| Closing inventory (consol) | ₹675 cr as of March 31, 2023 |